Drug cocktail shows promise in slowing return of ovarian cancer
NCT ID NCT02345265
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This phase 2 study tests whether combining two oral drugs, olaparib and cediranib, can help control recurrent ovarian, peritoneal, or fallopian tube cancer. About 70 participants with high-grade serous or endometrioid cancers are enrolled. The goal is to see if the combination can delay cancer progression and shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib and cediranib maleate (oral drugs)
- What this could lead to
- If successful, this combination could offer a new treatment option to control recurrent ovarian cancer and extend the time before the disease worsens.
- What could go wrong
- This is a mid-stage trial with only 70 participants, so results may not apply to everyone. The drugs can cause side effects, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Keck Medical Center of USC Pasadena
Pasadena, California, 91105, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NCI - Center for Cancer Research
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
New Brunswick, New Jersey, 08903, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can a custom vaccine train the body to fight ovarian cancer?
- Can engineered immune cells target a common ovarian cancer protein?
- Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a targeted drug boost standard ovarian cancer therapy?